Hangzhou Longshine Bio-Tech Co.,LTD
Note
The product under valid patents will not be offered to the countries covered by patents.
Contact Us
Address: 5-405,Matrix Int'l Ctr,NO.515 Yuhangtang Road,Gongshu District,Hangzhou,China 310011.
TEL: +86-571-28103536
FAX : +86-571-28103533
Website: www.longshinebiotech.com                 
Spironolact Weight Loss for Inhibition of Aldosterone Pharmaceutical Intermediates
- Aug 31, 2016 -

       

Basic Info.

       
Spironolact
       
Alias:Aldactone
       
CAS:52-1-7
       
Mf:C24h32o4s
       
MW:576.71
       
Einecs:200-133-6
       
Appearance:White Crystal Powder
       
Usage:Weight Loss Drugs
                  
Specification:Medicine Grade
                           

Product Description

Weight Loss drugs Spironolact CAS 52-1-7 For Inhibition Of Aldosterone
 
Appearance: White or white crystal powder of fine;Slightly bitter taste, odourless or slightly mercaptan odor.Insoluble in water
Usage:  is competitive inhibition of aldosterone drugs, drug itself is not active, role is diuresis and endogenous competitive aldosterone antagonist and happen, belongs to the potassium diuretics.
 
Description
commonly referred to simply as spiro, and marketed primarily under the brand name Aldactone in most countries, is a synthetic, steroidal antimineralocorticoid and antiandrogen that also has some weak progestogen properties, as well as some indirect estrogen and glucocorticoid effects. It is used primarily as a diuretic and antihypertensive, but may also be employed for the purpose of reducing elevated or unwanted androgen activity in the body. It acts predominantly as an antagonist of the mineralocorticoid (or aldosterone) and androgen receptors, and in relation to its antimineralocorticoid effects, belongs to a class of pharmaceutical drugs known as potassium-sparing diuretics.
  

 

 
Applications:

 is used primarily to treat heart failure, edematous conditions such as nephrotic syndrome or ascites in patients with liver disease, essential hypertension, hypokalemia, secondary hyperaldosteronism (such as occurs with hepatic cirrhosis), and Conn's syndrome (primary hyperaldosteronism). On its own.
Because spironolactone reduces the body's production of testosterone and blocks the androgen receptors, it can cause effects associated with low testosterone levels and hypogonadism in males. For this reason, men are typically not prescribed spironolactone for any longer than a short period of time, e.g. for an acute exacerbation of heart failure. The newer drug, eplerenone has been approved by the U.S. Food and Drug Administration for treatment of heart failure, but lacks the rather potent antiandrogen effects and thus is far more suitable for men for whom long term medication is being chosen. 
   

Contact US
 
Sales Manager
Tel  86-0571-28103536/0571-28103518/0571-28103530

Email:Sales@longshinebiotech.com